Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

675 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.
Ailawadhi S, Frank RD, Advani P, Swaika A, Temkit M, Menghani R, Sharma M, Meghji Z, Paulus S, Khera N, Hashmi SK, Paulus A, Kakar TS, Hodge DO, Colibaseanu DT, Vizzini MR, Roy V, Colon-Otero G, Chanan-Khan AA. Ailawadhi S, et al. Among authors: roy v. Cancer Med. 2017 Dec;6(12):2876-2885. doi: 10.1002/cam4.1246. Epub 2017 Nov 3. Cancer Med. 2017. PMID: 29105343 Free PMC article.
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Kapoor P, et al. Among authors: roy v. Blood. 2009 Jul 16;114(3):518-21. doi: 10.1182/blood-2009-01-202010. Epub 2009 Mar 26. Blood. 2009. PMID: 19324902 Free PMC article.
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Lacy MQ, et al. Among authors: roy v. J Clin Oncol. 2009 Oct 20;27(30):5008-14. doi: 10.1200/JCO.2009.23.6802. Epub 2009 Aug 31. J Clin Oncol. 2009. PMID: 19720894 Clinical Trial.
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV. Gay F, et al. Among authors: roy v. Blood. 2010 Feb 18;115(7):1343-50. doi: 10.1182/blood-2009-08-239046. Epub 2009 Dec 11. Blood. 2010. PMID: 20008302 Free PMC article.
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).
Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Lacy MQ, et al. Among authors: roy v. Leukemia. 2010 Nov;24(11):1934-9. doi: 10.1038/leu.2010.190. Epub 2010 Sep 9. Leukemia. 2010. PMID: 20827286 Free PMC article.
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.
Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, Gertz M, Kumar S, Mikhael J, Roy V, Kyle RA, Lacy MQ. Short KD, et al. Among authors: roy v. Leukemia. 2011 Jun;25(6):906-8. doi: 10.1038/leu.2011.29. Epub 2011 Feb 25. Leukemia. 2011. PMID: 21350560 Free PMC article. Clinical Trial.
675 results